Dr Sarah Staedke
MD PhD DTM&H
of Malaria & Global Health
I am a clinical epidemiologist with training in Internal Medicine (University of Colorado, Denver), Infectious Diseases (University of California, San Francisco), and Tropical Medicine (LSHTM). I have been involved in research on malaria since 1999, and am currently based in Uganda with the Infectious Diseases Research Collaboration. http://idrc-uganda.org/
Since 2007, I have served as a tutor and deputy module organiser for the distance-based learning course in malaria. I also sit on the Exam Boards for the East African DTM&H and the MSc in Tropical Medicine & International Health, and supervise MSc students from the distance-based learning programs in Public Health and Infectious Diseases.
My research is focused on P. falciparum malaria, including the efficacy and safety of antimalarial drugs, methods to improve quality of care and fever/malaria case management, surveillance to monitor the impact of malaria control interventions, and novel approaches to prevent and control malaria in Uganda.
Since 2009, I have served as the Deputy Director of the ACT Consortium, a global partnership of 17 institutions undertaking research on delivery of antimalarials in Africa and Asia. We conducted two projects funded by the ACT Consortium in Uganda, including a cluster randomized trial (PRIME) to evaluate the impact of a complex intervention delivered at public health centers on management of fever and malaria in children in Tororo, and a complementary mixed-methods study (PROCESS) to further our understanding about why the intervention was effective, or not. http://www.actconsortium.org/
I am particularly interested in intermittent preventive treatment (IPT) of malaria in schoolchildren and the role of chemoprevention in malaria control. We recently completed the START-IPT trial (School-based treatment with ACT to reduce transmission of malaria) in Jinja, Uganda. Conducted in 2013-15, this cluster-randomized trial assessed the impact of IPT for malaria in schoolchildren with dihydroartemisinin-piperaquine (DP) on community-level clinical outcomes and malaria transmission in Uganda.